Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: 2 | History Defined

AstraZeneca overtakes Pfizer as crunch week for UK pharma looms

Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results

The Guardian - UK

Moonpig flotation price, like so many, was always pie-in-the-sky thinking

You’d think fund mangers would have deployed degree of scepticism after years of overvalued businesses

The Guardian - UK

‘I no longer need a magnifying glass’: a visually impaired travel writer tests an app that ‘reads’ for him

Rob Crossan, a freelance journalist and radio presenter, has a visual impairment, and finds shopping for healthcare products less than straightforward. Will an app by Microsoft make it easier?

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

How a blind engineer developed an AI app to help people with sight loss

The designer of a groundbreaking text-reading app, that started life as a Microsoft side-project, explains how it’s now a lifeline for blind people and those with literacy issues

The Guardian - UK

‘PE was seen as a health and safety risk’: why sport must be accessible for people with sight loss

For blind and partially sighted people to experience the life-changing benefits of sport, more needs to be done to remove obstacles to participation

The Guardian - UK

‘The app gave me the information’: how technology enables visually impaired people to ‘see’

An app that can read out labels on healthcare products is at the cutting edge of a technology revolution that is helping improve accessibility for people with sight loss

The Guardian - UK

I tested an AI app for visually impaired people – and this is what I found

The Microsoft Seeing AI app aims to assist people who are visually impaired with buying health products. Elin Williams, 24, author of the disability and lifestyle blog My Blurred World, gives it a go – and reveals her verdict

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

The only party not getting heartburn over GSK demerger is the lawyers

The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years

The Guardian - UK

Sensodyne maker Haleon sees 22% profit rise in first results since GSK demerger

Haleon demerged from its parent company in July

Evening Standard

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Benzinga

Haleon’s debut suggests it may not be the jewel in GSK’s medicine cabinet

Consumer goods spin-off makes few waves in biggest European listing for more than a decade

The Guardian - UK

Benzinga Before The Bell: Amazon Wages Price War On Tesco, Biden's Campaign Promise To Free Cannabis Prisoners, H&M Exits Russia And Other Top Financial Stories Monday, July 18

Reuters GSK Completes Spin-Off Of Its Consumer Healthcare Business

Benzinga

Haleon provides temporary relief from London listings drought

Advisory fee bonanza will put bread on the tables of City corporate finance professionals

Evening Standard

City relief as GSK’s Haleon gets £31 billion float away

Panadol and Chapstick giant joins FTSE 100

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

GSK spin-off Haleon begins trading in biggest European listing in a decade

Consumer health company ends first day on London Stock Exchange with £28.5bn market valuation

Evening Standard

FTSE 100 Live: GSK’s Haleon makes stock market debut, Goldman banker pay down 40%

Consumer healthcare business Haleon makes its debut on the London stock market today after completing its demerger from GSK.

Benzinga

GSK Confirms Consumer Healthcare Unit Spin-off: What Investors Should Know

Close on the heels of an M&A deal, GlaxoSmithKline plc (NYSE: GSK) confirmed the spin-off of the consumer healthcare business it jointly owns with U.S. pharma giant Pfizer, Inc.

Benzinga

Morning Brief: Top Financial Stories Dominating on Wednesday, June 1

Reuters Redbird Capital Buys Italian Football Club AC Milan

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off

Pfizer Inc. (NYSE:PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE:GSK), after the business is spun out as an independent listed company in July, reported Reuters. Pfizer had previously indicated that it might seek to sell its stake in Haleon, a consumer health company and…

The Guardian - UK

BP and Shell lead rush to exit Russia. There can be no going back

Oil is always a political business, and there’s no point pretending otherwise

The Guardian - UK

GSK boss upbeat over spin-off of consumer healthcare unit

Expected to be the biggest London listing in a decade, the Haleon demerger is scheduled for July

The Guardian - UK

GSK unveils its new consumer brands spin-off name: Haleon

Products such as Voltaren, Sensodyne and Panadol to regroup under new stock market listing in summer

Evening Standard

Hello, Haleon: GlaxoSmithKline reveals name of £60bn consumer health spin-out

THE new consumer healthcare company to be spun out from GlaxoSmithKline will be named Haleon, it was announced today.

The Guardian - UK

Oil prices hit seven-year highs close to $100 after Russia moves troops into Ukraine – as it happened

Germany pulls plug on Nord Stream 2 pipeline, as UK and European shares see-saw and rouble sinks to two-year low

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations